• Economy
  • Editor’s Pick
Money Rise Today – Investing and Stock News
  • Investing
  • Stock
Stock

Elon Musk’s Neuralink raises $650 million in fresh capital

by June 3, 2025
written by June 3, 2025

Elon Musk’s brain tech startup Neuralink has closed a $650 million funding round, the company announced Monday.

ARK Invest, Founders Fund, Sequoia Capital, Thrive Capital, Lightspeed Venture Partners and other firms participated in the round, according to a press release. Neuralink said the fresh capital will help the company bring its technology to more patients and develop new devices that “deepen the connection between biological and artificial intelligence.”

Neuralink is building a brain-computer interface, or BCI, which is a system that translates brain signals into commands for external technologies.

The company’s first system, called Telepathy, involves 64 “threads” that are inserted directly into the brain. The threads are thinner than a human hair and record neural signals through 1,024 electrodes, according to Neuralink’s website.

The initial aim of the technology is to help patients with severe paralysis restore some independence. As of Monday, five patients have been implanted with Neuralink’s technology, and are able to “control digital and physical devices with their thoughts,” the release said.

Neuralink is currently carrying out four separate clinical trials around its Telepathy system.

BCIs have been studied in academia for decades, and several other companies, including Synchron, Paradromics and Precision Neuroscience, are developing their own systems.

Paradromics on Monday announced it successfully implanted its BCI in a human for the first time.

It’s not clear what devices Neuralink will look to develop next, but Musk has for years espoused grand ambitions for the brain tech startup. He has even claimed that he would be willing to get an implant himself.

One of the capabilities Musk has repeatedly highlighted is the ability to restore vision to blind patients.

Neuralink received a “Breakthrough Device” designation from the U.S. Food and Drug Administration for a device called Blindsight. This designation is granted to medical devices that have the potential to provide improved treatment for debilitating or life-threatening conditions.

In a post on his social media platform X in September, Musk said Blindsight will enable even those who have lost both eyes and their optic nerve to see.

Neuralink still has a long road ahead before it can commercialize these technologies.

This post appeared first on NBC NEWS
0 comment
0
FacebookTwitterPinterestEmail

previous post
House Dems urge GOP to condemn DHS for handcuffing Rep Nadler staffer, order Noem to testify
next post
Uber delivery chief Gore-Coty is leaving after almost 13 years at ride-hailing company

related articles

Trump administration alleges Nike discriminated against white workers

March 13, 2026

Retail operator of outdoor sportswear pioneer Eddie Bauer...

March 13, 2026

Landmark trial accusing social media companies of addicting...

March 13, 2026

Justice Department’s antitrust chief says she’s leaving, effective...

March 13, 2026

Cardi B’s cameo in Bad Bunny’s Super Bowl...

March 13, 2026

Warner Bros. Discovery reopens talks with Paramount

March 13, 2026

CFTC chief sides with prediction markets over state...

March 13, 2026

DOJ takes Live Nation-Ticketmaster to court for antitrust...

March 13, 2026

L.A. County sues Roblox, alleges platform makes it...

March 13, 2026

United Airlines says it will boot passengers who...

March 13, 2026
Enter Your Information Below To Receive Free Trading Ideas, Latest News, And Articles.


Your information is secure and your privacy is protected. By opting in you agree to receive emails from us. Remember that you can opt-out any time, we hate spam too!

Latest News

  • Trump invites Putin, Lukashenko to join Gaza ‘Board of Peace,’ Russia and Belarus say

    January 19, 2026
  • Top House committees accuse Dem fundraising giant of facilitating ‘bad actors’ in bombshell DOJ letter

    May 7, 2025
  • 3 key takeaways from Trump’s push to put US oil firms back in Venezuela

    January 5, 2026
  • Biden ends bid for second term in White House as he drops out of his 2024 rematch with Trump

    July 21, 2024
  • Sam Altman tells OpenAI staff there’s no plan for him to receive ‘giant equity stake’ in company

    September 30, 2024

Popular Posts

  • 1

    District judges’ orders blocking Trump agenda face hearing in top Senate committee

    April 2, 2025
  • 2

    Secret Service admits leaning on ‘state and local partners’ after claim it ignored Trump team’s past requests

    July 21, 2024
  • 3

    Five more House Democrats call on Biden to drop out, third US senator

    July 19, 2024
  • 4

    Forex Profit Calculator: Maximize Your Trading Potential

    July 10, 2024
  • 5

    CoreWeave eyes $1.5B bond raise to ease debt load following lacklustre IPO: report

    May 9, 2025

Categories

  • Economy (829)
  • Editor's Pick (8,376)
  • Investing (1,315)
  • Stock (981)

Latest Posts

  • CDC seems to defy Trump executive order by participating in WHO vaccine conference

    February 26, 2025
  • Dogecoin and Shiba Inu: Dogecoin pulled back to a new low

    August 6, 2024
  • Marco Rubio says Nicolás Maduro’s Cartel de los Soles to be designated a terrorist organization

    November 17, 2025

Recent Posts

  • Biden camp skipped Super Bowl interview amid Robert Hur report concerns: source

    August 8, 2025
  • Trump reacts to Secret Service director resigning: ‘She never gave me proper protection’

    July 23, 2024
  • Embraer CEO says jet maker studying possibilities for a new aircraft

    October 21, 2024

Editor’s Pick

  • Marjorie Taylor Greene shares what’s next for House DOGE panel, whether Elon Musk would testify

    February 12, 2025
  • Iran threatens ‘nightmare’ for Israel as UN watchdog warns Tehran nuclear programs runs unchecked

    September 9, 2024
  • ‘John Brennan, Gina Haspel era is over’: Ratcliffe, allies promise workforce changes at CIA

    January 28, 2025
  • About us
  • Contacts
  • Privacy Policy
  • Terms & Conditions

Disclaimer: moneyrisetoday.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

Copyright © 2025 moneyrisetoday.com | All Rights Reserved

Money Rise Today – Investing and Stock News
  • Economy
  • Editor’s Pick
Money Rise Today – Investing and Stock News
  • Investing
  • Stock